Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36099926

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2022 Oct 1
First author
Pal SK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2022 Oct 1;400(10358):1080-1081. doi: 10.1016/S0140-6736(22)01747-0.
    note
    Source null
    related pmid
    36099928
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Feb;20(2):65-66. doi: 10.1038/s41571-022-00710-5.
    note
    Source null
    related pmid
    36418478
    relationship
    Comment in
  3. citation
    Eur Urol. 2023 Mar;83(3):297-298. doi: 10.1016/j.eururo.2022.11.010.
    note
    Source null
    related pmid
    36464531
    relationship
    Comment in
  4. citation
    Eur Urol. 2023 May;83(5):475-476. doi: 10.1016/j.eururo.2022.12.025.
    note
    Source null
    related pmid
    36609006
    relationship
    Comment in
  5. citation
    J Urol. 2023 Apr;209(4):804-806. doi: 10.1097/JU.0000000000003171.
    note
    Source null
    related pmid
    36660916
    relationship
    Comment in
  6. citation
    Lancet. 2023 Jul 15;402(10397):181. doi: 10.1016/S0140-6736(23)01067-X.
    note
    Source null
    related pmid
    37453746
    relationship
    Comment in

Authors and identifiers

  1. name
    Pal SK
    type
    Author
  2. name
    Uzzo R
    type
    Author
  3. name
    Karam JA
    type
    Author
  4. name
    Master VA
    type
    Author
  5. name
    Donskov F
    type
    Author
  6. name
    Suarez C
    type
    Author
  7. name
    Albiges L
    type
    Author
  8. name
    Rini B
    type
    Author
  9. name
    Tomita Y
    type
    Author
  10. name
    Kann AG
    type
    Author
  11. name
    Procopio G
    type
    Author
  12. name
    Massari F
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Pal SK
    type
    Author
  2. name
    Uzzo R
    type
    Author
  3. name
    Karam JA
    type
    Author
  4. name
    Master VA
    type
    Author
  5. name
    Donskov F
    type
    Author
  6. name
    Suarez C
    type
    Author
  7. name
    Albiges L
    type
    Author
  8. name
    Rini B
    type
    Author
  9. name
    Tomita Y
    type
    Author
  10. name
    Kann AG
    type
    Author
  11. name
    Procopio G
    type
    Author
  12. name
    Massari F
    type
    Author
bibliography ids
  1. nci-bib-19032eed859bbe82ea481d8b
book metadata
content sha256
f6b40a80a70cfefa706d54220e92a97d77ff8c9cbef073d5c41ecedaddb8ef2f
document type
citation
dois
  1. 10.1016/S0140-6736(22)01658-0
electronic publication date
display
2022 Sep 10
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36099926
immutable id
pubmed:36099926@f6b40a80a70cfefa706d54220e92a97d77ff8c9cbef073d5c41ecedaddb8ef2f
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10358
name
Lancet (London, England)
nlm unique id
2985213R
pages
1103-1116
volume
400
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2022 Oct 1;400(10358):1080-1081. doi: 10.1016/S0140-6736(22)01747-0.
    note
    Source null
    related pmid
    36099928
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Feb;20(2):65-66. doi: 10.1038/s41571-022-00710-5.
    note
    Source null
    related pmid
    36418478
    relationship
    Comment in
  3. citation
    Eur Urol. 2023 Mar;83(3):297-298. doi: 10.1016/j.eururo.2022.11.010.
    note
    Source null
    related pmid
    36464531
    relationship
    Comment in
  4. citation
    Eur Urol. 2023 May;83(5):475-476. doi: 10.1016/j.eururo.2022.12.025.
    note
    Source null
    related pmid
    36609006
    relationship
    Comment in
  5. citation
    J Urol. 2023 Apr;209(4):804-806. doi: 10.1097/JU.0000000000003171.
    note
    Source null
    related pmid
    36660916
    relationship
    Comment in
  6. citation
    Lancet. 2023 Jul 15;402(10397):181. doi: 10.1016/S0140-6736(23)01067-X.
    note
    Source null
    related pmid
    37453746
    relationship
    Comment in
outcomes validated
false
pmid
36099926
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
8d86187c5322e24fe988ee601d2f0f419c470a482e908d8b8963c9d615ba5856
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Oct 1
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36099926/
title
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.

Preserved source evidence · Not medical advice